TB-500 is a synthetic peptide fragment derived from Thymosin Beta-4, widely used in preclinical research focused on tissue healing, angiogenesis and inflammation modulation. It interacts with actin proteins within cells to promote cell migration, accelerate blood vessel formation and regulate local inflammatory response at injury sites. In animal laboratory studies, TB-500 is commonly applied in research models of muscle strains, tendon injuries, ligament damage, skin wounds and joint trauma, investigating its potential effects on tissue recovery.

Manufactured by mature solid-phase peptide synthesis process, crude peptide undergoes multi-step reversed-phase HPLC purification to remove truncated peptide fragments, oxidized impurities and residual organic solvents. Every batch is equipped with full COA certification, including HPLC purity test, MS molecular weight confirmation, moisture content detection, residual solvent analysis, endotoxin inspection and microbial limit test to ensure stable batch consistency. The lyophilized powder form effectively reduces peptide hydrolysis and degradation, retaining high stability during cross-border transportation and long-term sample preservation. Suitable research scenarios cover in vitro cell migration assays, angiogenesis mechanism study, in vivo animal wound and soft tissue injury model evaluation, as well as peptide stability testing.